Genelux (NASDAQ:GNLX) SVP Yong Yu Sells 3,219 Shares of Stock

Genelux Corporation (NASDAQ:GNLX) SVP Yong Yu sold 3,219 shares of the company’s stock in a transaction on Thursday, August 21st. The stock was sold at an average price of $3.36, for a total transaction of $10,815.84. Following the completion of the transaction, the senior vice president owned 146,817 shares of the company’s stock, valued at $493,305.12. This trade represents a 2.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Yong Yu also recently made the following trade(s):

• On Monday, November 17th, Yong Yu sold 973 shares of Genelux stock. The shares were sold at an average price of $5.37, for a total transaction of $5,225.01.

Genelux Stock Performance

Shares of NASDAQ GNLX traded down $0.11 during midday trading on Thursday, hitting $4.40. 77,387 shares of the company traded hands, compared to its average volume of 191,698. Genelux Corporation has a 12-month low of $1.99 and a 12-month high of $8.53. The firm has a market cap of $167.42 million, a P/E ratio of -5.00 and a beta of 0.06. The stock has a 50-day moving average price of $5.74 and a 200 day moving average price of $4.17.

Genelux (NASDAQ:GNLX) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.02. As a group, equities analysts expect that Genelux Corporation will post -0.88 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Private Management Group Inc. bought a new stake in Genelux in the second quarter worth $33,000. American Century Companies Inc. bought a new position in shares of Genelux during the first quarter valued at $51,000. Beacon Capital Management LLC raised its position in shares of Genelux by 99.8% in the 2nd quarter. Beacon Capital Management LLC now owns 19,116 shares of the company’s stock worth $55,000 after purchasing an additional 9,550 shares during the last quarter. Falcon Wealth Planning boosted its stake in Genelux by 83.3% in the 2nd quarter. Falcon Wealth Planning now owns 22,000 shares of the company’s stock worth $63,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. bought a new position in Genelux in the 1st quarter worth about $68,000. Hedge funds and other institutional investors own 37.33% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on GNLX shares. Weiss Ratings restated a “sell (e+)” rating on shares of Genelux in a research report on Wednesday, October 8th. Lake Street Capital initiated coverage on Genelux in a research report on Tuesday, October 21st. They set a “buy” rating and a $16.00 price objective for the company. Loop Capital set a $16.00 target price on shares of Genelux in a report on Tuesday, October 21st. Finally, Maxim Group set a $20.00 price target on shares of Genelux in a research note on Tuesday, October 21st. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $21.00.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.